This year’s virtual International Workshop on Non-Hodgkin Lymphoma (iwNHL) highlighted key progress in our understanding of various non-Hodgkin lymphoma (NHL) subtypes, the role of the immune microenvironment, as well as evaluating novel therapeutic strategies in development for patients with NHL.

In this podcast, John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, of Barts Cancer Institute, London, UK, chairs a compelling discussion on key highlights from the iwNHL 2020 virtual meeting, including the next questions from the results of the KEYNOTE-204 trial in Hodgkin lymphoma, the significance of immunotherapy and the microenvironment, and an overview of exciting novel agents in NHL. Prof. Gribben is joined by Peter Borchmann, MD, of the University Hospital Cologne, Cologne, Germany, Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, and Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN.